Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iradimed (IRMD) EPS (Weighted Average and Diluted) (2016 - 2025)

Iradimed (IRMD) has disclosed EPS (Weighted Average and Diluted) for 13 consecutive years, with $0.5 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 25.0% to $0.5 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.75 through Dec 2025, up 16.67% year-over-year, with the annual reading at $1.75 for FY2025, 16.67% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.5 at Iradimed, up from $0.43 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.5 in Q4 2025, with the low at $0.11 in Q1 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.32, with a median of $0.32 recorded in 2023.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 520.0% in 2021, while the deepest fall reached 21.43% in 2021.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at $0.31 in 2021, then decreased by 3.23% to $0.3 in 2022, then grew by 20.0% to $0.36 in 2023, then grew by 11.11% to $0.4 in 2024, then rose by 25.0% to $0.5 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at $0.5, $0.43, and $0.45 for Q4 2025, Q3 2025, and Q2 2025 respectively.